Oteracil potassium | CAS#2207-75-2 | Urate oxidase antagonist

MedKoo Cat#: 558588 | Name: Oteracil potassium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oteracil potassium is an antagonist of urate oxidase. It is used to induce hyperuricemia in mice.

Chemical Structure

Oteracil potassium

CAS#2207-75-2

Theoretical Analysis

MedKoo Cat#: 558588

Name: Oteracil potassium

CAS#: 2207-75-2

Chemical Formula: C4H2KN3O4

Exact Mass: 194.9682

Molecular Weight: 195.18

Elemental Analysis: C, 24.62; H, 1.03; K, 20.03; N, 21.53; O, 32.79

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
5g	USD 550.00	2 Weeks
25g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Oteracil potassium; Oxonic acid potassium salt; Oxonate, potassium; Potassium azaorotate; Potassium oxonate;

IUPAC/Chemical Name

Potassium 1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-2-carboxylate

InChi Key

IAPCTXZQXAVYNG-UHFFFAOYSA-M

InChi Code

InChI=1S/C4H3N3O4.K/c8-2(9)1-5-3(10)7-4(11)6-1;/h(H,8,9)(H2,5,6,7,10,11);/q;+1/p-1

SMILES Code

O=C(C(NC1=O)=NC(N1)=O)[O-].[K+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Oteracil potassium is an antagonist of urate oxidase.

In vitro activity:

TBD

In vivo activity:

On p.o. administration of 5-FU (2 mg/kg) and a potent inhibitor of 5-FU degradation to Yoshida sarcoma-bearing rats, oxonic acid (10 mg/kg) was found to inhibit the formation of 5-fluorouridine-5'-monophosphate from 5-FU and its subsequent incorporation into the RNA fractions of small and large intestine but not of tumor and bone marrow tissues. Reference: Cancer Res. 1993 Sep 1;53(17):4004-9. https://pubmed.ncbi.nlm.nih.gov/7689420/

	Solvent	mg/mL	mM
Solubility
	PBS (pH 7.2)	0.3	1.54
	Water	5.7	29.03

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 195.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Eräranta A, Kurra V, Tahvanainen AM, Vehmas TI, Kööbi P, Lakkisto P, Tikkanen I, Niemelä OJ, Mustonen JT, Pörsti IH. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008 Aug;26(8):1661-8. doi: 10.1097/HJH.0b013e328303205d. PMID: 18622246. 2. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993 Sep 1;53(17):4004-9. PMID: 7689420.

In vitro protocol:

TBD

In vivo protocol:

1: Li YJ, Yuan P, Zhai JN, Yao YF, Tan LX, Li ZW, Zhang XY, Wu AW. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction]. Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Jul 25;27(7):684-693. Chinese. doi: 10.3760/cma.j.cn441530-20240526-00188. PMID: 39004983. 2: Song J, Zhou H, Sun C, Jiao L, Gong Y, Yao J, Xu L. Combination of Brucea javanica oil emulsion and Aidi injection associated with the long‑term survival of a patient with colon cancer and lung metastases post‑chemotherapy: A case report. Oncol Lett. 2024 Jun 6;28(2):361. doi: 10.3892/ol.2024.14494. PMID: 38895054; PMCID: PMC11184358. 3: Shimada A, Iida M, Murakami K, Ichioka S, Harano A, Tanito M. A Case of Corneal Thinning During S-1 Oral Administration. Cureus. 2024 Apr 15;16(4):e58356. doi: 10.7759/cureus.58356. PMID: 38756279; PMCID: PMC11097295. 4: Furukawa K, Hatakeyama K, Terashima M, Urakami K, Koseki Y, Fujiya K, Tanizawa Y, Bando E, Yamaguchi K. Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer. Gastric Cancer. 2024 Jul;27(4):760-771. doi: 10.1007/s10120-024-01506-5. Epub 2024 May 14. PMID: 38744779. 5: Yoshikawa T, Kikko Y, Makino R, Kimijima Y, Nishiyama E, Matsuda Y, Casaes Teixeira B, Tejada M, Carroll R, Hironaka S. Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in japan: a retrospective database cohort study. Gastric Cancer. 2024 Jul;27(4):827-839. doi: 10.1007/s10120-024-01501-w. Epub 2024 Apr 30. PMID: 38689045; PMCID: PMC11193688. 6: Hatta N, Ogata D, Asai J, Maekawa T, Ito T, Takenouchi T, Kiniwa Y, Miyashita A, Miyagawa T, Muto I, Yamamoto Y, Nagano T, Kiyohara Y, Nakano E, Ohe S, Yamaguchi B, Fukuyama M, Matsuya T, Tsutsumida A, Namikawa K, Yamazaki N. Recent treatment and prognosis in 643 patients with extramammary Paget's disease. Exp Dermatol. 2024 Feb;33(2):e15030. doi: 10.1111/exd.15030. PMID: 38375900. 7: Yuan C, Wu S, Wu Y, Tian C, Wang Z, Zhang X. Effects of Traditional Chinese Medicine "Fuzheng Qingdu Decoction" on Autonomic Function and Cancer-Related Symptoms in Patients with Advanced Gastric Cancer undergoing Chemotherapy: A Controlled Trial. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241229414. doi: 10.1177/15347354241229414. PMID: 38323452; PMCID: PMC10851715. 8: Yang Z, Lu S, Shi M, Yuan H, Wang Z, Ni Z, He C, Zheng Y, Zhu Z, Liu W, Yao X, Zhang J, Li C, Yan M, Yan C, Zhu Z. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study. Gastric Cancer. 2024 Mar;27(2):387-399. doi: 10.1007/s10120-023-01452-8. Epub 2023 Dec 24. PMID: 38143257; PMCID: PMC10896904. 9: Kitadani J, Ojima T, Hayata K, Goda T, Takeuchi A, Tominaga S, Fukuda N, Nakai T, Yamaue H, Kawai M. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis. Oncology. 2024;102(3):228-238. doi: 10.1159/000533790. Epub 2023 Sep 14. PMID: 37708864. 10: Zhang TW, Zhang P, Nie D, Che XY, Fu TT, Zhang Y. Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers. World J Gastrointest Oncol. 2023 Jul 15;15(7):1262-1270. doi: 10.4251/wjgo.v15.i7.1262. PMID: 37546558; PMCID: PMC10401474. 11: Yamada M, Iijima Y, Seo M, Hino S, Sano M, Sakagami H, Horie N, Kaneko T. Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa. In Vivo. 2023 Jul-Aug;37(4):1880-1885. doi: 10.21873/invivo.13280. PMID: 37369479; PMCID: PMC10347951. 12: Qu FJ, Wu S, Kong Y. Oral fruquintinib combined with tegafur-gimeracil- oteracil potassium for advanced colorectal cancer to obtain longer progression- free survival: A case report. World J Gastrointest Oncol. 2023 May 15;15(5):902-910. doi: 10.4251/wjgo.v15.i5.902. PMID: 37275454; PMCID: PMC10237021. 13: Zheng J, Wang S, Xu G, Wang J, Wang Y, Luo J, Wang Y, Yang J. A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial. J Gastrointest Oncol. 2023 Apr 29;14(2):1131-1140. doi: 10.21037/jgo-23-131. Epub 2023 Apr 27. PMID: 37201078; PMCID: PMC10186493. 14: Tsuchiya M, Obara T, Kikuchi M, Mano N. The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database. Cancer Chemother Pharmacol. 2023 Jun;91(6):501-506. doi: 10.1007/s00280-023-04535-6. Epub 2023 May 8. PMID: 37150758. 15: Ushigome M, Funahashi K, Kaneko T, Kagami S, Yoshida K, Miura Y, Koda T, Nagashima Y, Kurihara A, Terahara A. Efficacy and safety of preoperative chemoradiotherapy with S-1 for advanced rectal cancer: a phase II study. Rep Pract Oncol Radiother. 2023 Apr 6;28(1):36-46. doi: 10.5603/RPOR.a2023.0005. PMID: 37122915; PMCID: PMC10132197. 16: Shibamoto Y, Takano S. Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects. Cancers (Basel). 2023 Mar 20;15(6):1864. doi: 10.3390/cancers15061864. PMID: 36980750; PMCID: PMC10046665. 17: Chen M, Yao X, Ping J, Shen H, Wei Y, Wang WL. Switch/Sucrose Non- Fermentable Complex-Deficient Rhabdoid Carcinoma of Stomach: A Rare Case Report and Literature Review. Int J Surg Pathol. 2023 Oct;31(7):1364-1374. doi: 10.1177/10668969221146204. Epub 2023 Mar 9. PMID: 36895105. 18: Zhang W, Sun Y, Jiang Z, Qu W, Gong C, Zhou A. Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial. Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):37-44. doi: 10.21037/hbsn-21-172. Epub 2021 Oct 18. PMID: 36860259; PMCID: PMC9944545. 19: Zhan G, Hu J, Da S, Weng J, Zhou C, Wen F, Liu S, Fang F, Shen E, Zhou Q, Luo P, Xu M, Zhan D, Su Y. A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Front Endocrinol (Lausanne). 2023 Jan 20;14:1110624. doi: 10.3389/fendo.2023.1110624. PMID: 36742383; PMCID: PMC9897321. 20: Wang N, Xu J, Wang G, Cao P, Ye X. Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study. J Cancer Res Ther. 2022 Dec;18(7):1945-1951. doi: 10.4103/jcrt.jcrt_819_22. PMID: 36647954.